GW Pharmaceuticals plc (AIM: GWP) welcomes the publication today by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) of a Public Information Report on Sativex, GW’s cannabinoid spray medicine.
The MHRA has taken this unprecedented step due to its view of the “huge public interest” in Sativex and the fact that approximately 1400 patients in the UK have so far received the medicine on prescription on a named patient basis. New patients continue to be prescribed Sativex every day. Hence, the MHRA considers that it is in the public interest for potential prescribers to have further information on the medicine.
Dr Geoffrey Guy, Chairman, said, “We welcome the MHRA’s appreciation of the public interest in Sativex and recognition of the extent of prescription use of Sativex in the UK. We continue to receive enquiries from UK physicians and patients on a daily basis and this report will serve to provide them with more information about the medicine and its use.”
Dr Guy added, “As we have previously announced, there is an outstanding efficacy issue to be resolved prior to full regulatory approval for Sativex in the relief of Multiple Sclerosis spasticity. This issue, detailed in the report, is being addressed through an additional Phase III clinical trial, which commenced recently.”